FINDING THE OPTIMAL TREATMENT STRATEGY FOR DISEASE ACTIVITY-GUIDED DOSE REDUCTION OF ADALIMUMAB AND ETANERCEPT IN RHEUMATOID ARTHRITIS: A MODELLING STUDY

被引：0
|
作者：
Verhoef, L. M. [1 ]
Bos, D. P. [1 ]
van den Ende, C. H. [1 ,2 ]
van den Hoogen, F. H. [1 ,2 ]
Fautrel, B. [3 ]
Hulscher, M. E. [4 ]
Kievit, W. [5 ]
den Broeder, A. A. [1 ,2 ]
机构：
[1] St Maartenskliniek, Rheumatol, Nijmegen, Netherlands
[2] Radboudumc, Rheumatol, Nijmegen, Netherlands
[3] Hop La Pitie Salpetriere, Rheumatol, Paris, France
[4] RIHS, IQ Healthcare, Nijmegen, Netherlands
[5] Radboudumc, RIHS, Hlth Evidence, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2604
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0207
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [31] The 6-month change in disease activity and disability after treatment with adalimumab compared to etanercept and infliximab in patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Brus, H. C.
    De Gendt, C. M.
    Jansen, T. L.
    Janson, M.
    Kupper, H. H.
    Moolenburgh, J. D.
    Van Oijen, P. L. M.
    D'Amelio, R.
    Ronday, K. H.
    De Rooij, D. J. R. A.
    Adang, E. E.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [32] Implementation of a tightly controlled dose reduction strategy of adalimumab, etanercept and ustekinumab for psoriasis in daily clinical practice: a pilot study
    van der Schoot, L.
    Bastiaens, M.
    de Boer-Brand, A.
    Christiaansen-Smit, C.
    Enomoto, D.
    Hovingh, R.
    Tupker, R.
    van den Reek, J.
    de Jong, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E38 - E38
  • [33] Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
    Louis Bessette
    Majed Khraishi
    Alan J. Kivitz
    Arunan Kaliyaperumal
    Rama Grantab
    Melanie Poulin-Costello
    Maya Isaila
    David Collier
    Rheumatology and Therapy, 2017, 4 : 391 - 404
  • [34] Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
    Thorne, Carter
    Boire, Gilles
    Chow, Andrew
    Garces, Kirsten
    Poulin-Costello, Melanie
    Walker, Valery
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1171 - 1171
  • [35] Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement
    Bouman, C. A. M.
    van Herwaarden, N.
    van den Hoogen, F. H. J.
    van der Maas, A.
    van den Bemt, B. J. F.
    den Broeder, A. A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (06) : 597 - 603
  • [36] Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
    Bessette, Louis
    Khraishi, Majed
    Kivitz, Alan J.
    Kaliyaperumal, Arunan
    Grantab, Rama
    Poulin-Costello, Melanie
    Isaila, Maya
    Collier, David
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 391 - 404
  • [37] Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
    Thorne, J. Carter
    Boire, Gilles
    Chow, Andrew
    Garces, Kirsten
    Liu, Fang
    Poulin-Costello, Melanie
    Walker, Valery
    Haraoui, Boulos
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [38] Remission and minimal disease activity in patients with active rheumatoid arthritis (RA) after treatment with adalimumab
    Burmester, G. R.
    Ferraccioli, G. F.
    Flipo, R.
    Kary, S.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 164 - 165
  • [39] Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
    Aneela N. Mian
    Fowzia Ibrahim
    David L. Scott
    James Galloway
    Arthritis Research & Therapy, 18
  • [40] Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study
    Schabert, V. F.
    Bruce, B.
    Ferrufino, C. F.
    Globe, D. R.
    Harrison, D. J.
    Lingala, B.
    Fries, J. F.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 569 - 580
12345